The Food and Drug Administration last week approved donanemab, or Kisunla, an intravenous treatment for early stage Alzheimer ...

Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...

The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

Washington — U.S. officials have approved another Alzheimer’s drug that can modestly ... to get a prescription. The FDA approved Kisunla, known chemically as donanemab, based on results ...

Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...

The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...

The latest drug is showing promising results for adults with early Alzheimer's symptoms, mild cognitive impairment (MCI), and ...

Longeveron Inc. (LGVN) said Wednesday that the U.S. Food and Drug Administration has granted Fast Track designation to Lomecel-B for ...

LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced that its primary treatment, Lomecel-B, has been granted Fast Track designation by the FDA only a week after being granted ...

Among these, in June, Tiziana Life Sciences received Food and Drug Administration clearance to use intranasal foralumab in its first patient with moderate Alzheimer’s disease under the FDA’s Expanded ...

Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive problems, according to an ...

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline ...